Kallyope Revenue and Competitors
Estimated Revenue & Valuation
- Kallyope's estimated annual revenue is currently $17.1M per year.
- Kallyope received $21.0M in venture funding in December 2018.
- Kallyope's estimated revenue per employee is $155,000
- Kallyope's total funding is $479M.
- Kallyope's current valuation is $1.2B. (February 2022)
- Kallyope has 110 Employees.
- Kallyope grew their employee count by 26% last year.
Kallyope Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Kallyope?
Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company integrates cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics and products that improve human health. The company's founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D. and Nobel laureate Richard Axel, M.D. Headquartered at the Alexandria Center® for Life Science in New York City. We currently have many openings across Kallyope and are searching for great candidates to become part of a highly integrated team working on the cutting edge of science to identify new approaches to human health. Check out our available jobs on our website, www.kallyope.com/careers. Don't see a position that interests you Email us anyway at firstname.lastname@example.org. We want to know you better.keywords:Biotechnology,Healthcare
Number of Employees
Employee Growth %
Kallyope, headquartered at the Alexandria Center® for Life Science in New York City, is a biotechnology company dedicated to unlocking the...
NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Kallyope Inc., a leading biotechnology company focused on identifying and pursuing novel therapeutics involving the gut-brain axis, today announced that the Board of Directors has appointed Jay Galeota as President and he will succeed Nancy Thornberry as ...
Kallyope set out in 2015 with $44 million and a mission to map out the “information highway” between the gut and the brain. Four years later, the company is gearing up to take its first program into the clinic, and it’s bagged $112 million to do so. Sponsored by Agilent Technologies How would ...
Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced a $112 million Series C financing. This financing will be used to advance its portfolio of programs and the company's first clinical trials, ...
NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|